|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.8 SEK | -0.23% |
|
+0.92% | +31.14% |
| 22/04 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
| 13/02 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
EQL Pharma AB (publ) reported earnings results for the first quarter ended June 30, 2023. For the first quarter, the company reported sales was SEK 56.21 million compared to SEK 46.1 million a year ago. Net income was SEK 6.83 million compared to SEK 7.39 million a year ago.
Basic earnings per share from continuing operations was SEK 0.23 compared to SEK 0.25 a year ago. Diluted earnings per share from continuing operations was SEK 0.23 compared to SEK 0.25 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +31.14% | 117M | |
| -34.03% | 14.86B | |
| -23.66% | 11.73B | |
| +16.46% | 6.3B | |
| -25.24% | 6.29B | |
| -9.39% | 6B | |
| -2.34% | 4.63B | |
| +60.00% | 4.57B | |
| -8.19% | 3.5B | |
| -6.41% | 3.04B |
EQL PHARMA AB 